MTOR and metabolic dysfunction-associated steatotic liver disease: In summary, this study demonstrates that administration of hUC-MSCs alleviates steatosis, inflammation and fibrosis in NAFLD via inducing autophagy, which is mediated through the AMPK-mTOR-TFEB signaling pathway.